Moderate to severe chronic obstructive pulmonary disease
Conditions
Interventions
Intervention group:Budesonide/formoterol (Symbicort
160 µg/4.5 µg
1 suction/time, 2 times/day)
treatment of tiotropium bromide (Spiriva
1.8 µg inhaled once a day before sleeping).
Control group:Bbudesonide/formoterol (Symbicort
1 suction/time, 2 times/day).
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged >18 years; patients who were diagnosed with group B and C COPD in accordance with the Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (revised edition from 2013), published by the COPD Group of the Chinese Thoracic Society; patients who received inhalation therapy; patients who didnt receive any cholinolytic drugs within 4 weeks; patients who didnt suffer from any acute attack and didnt receive any antibiotic therapy within 4 weeks; patients who had not received any systemic glucocorticoid therapy in the past two months; patients who provided written informed consent.
Exclusion criteria
Exclusion criteria: Patients who were allergic to tiotropium bromide, budesonide/formoterol inhalation or any other inhaled ingredients; patients with diseases rendering them unsuitable for inhalation therapy, including bronchial lung cancer, dilatation and interstitial lung diseases; patients suffering from other systemic diseases, including heart, liver, kidney, hematopoietic and nervous system diseases, glaucoma or severe prostatic hyperplasia; patients who were considered unsuitable for participating in the drug trial by the clinicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lung function;Body mass index;The dyspnea score;The six-minute walking test;Health-associated quality of life;Prognosis and safety indices; | — |
Countries
China
Contacts
Public ContactHua Xu
The First Affiliated Hospital of Soochow University
Outcome results
None listed